Exocell—糖尿病研究相關(guān)產(chǎn)品

Exocell公司是一家專注于糖尿病及其并發(fā)癥研究相關(guān)的產(chǎn)品與服務(wù)美國高科技生物制品公司，該公司提供先進(jìn)的糖尿病研究產(chǎn)品，涵蓋臨床診斷、臨床研究及基礎(chǔ)實(shí)驗(yàn)研究領(lǐng)域，包括人、小鼠、 大鼠尿蛋白和糖基化蛋白，人纖連蛋白、載脂蛋白B等一系列試劑盒和抗體，其高品質(zhì)的產(chǎn)品歐美。作為開發(fā)，營銷和執(zhí)行新的臨床診斷化驗(yàn)*者，Exocell公司已經(jīng)并且正在為糖尿病及其相關(guān)的腎臟和血管疾病領(lǐng)域的基礎(chǔ)科研、實(shí)驗(yàn)動(dòng)物研究以及臨床診斷和治療研究提供的產(chǎn)品和研發(fā)服務(wù)。

Exocell公司的主要產(chǎn)品：

一、臨床診斷檢測對(duì)于糖尿病及其并發(fā)癥的治療和管理至關(guān)重要，在該領(lǐng)域中Exocell公司提供的臨床診斷相關(guān)產(chǎn)品包括：

Albuwell用于檢測微白蛋白尿，是早期糖尿病性腎功能紊亂的明確標(biāo)志物。

Creatinine用于檢測尿中的creatinine.

Glycaben用于監(jiān)測糖化白蛋白（中期的控糖指標(biāo)）

Glycacor用于檢測糖化LDL（短期控糖指標(biāo)及心血管疾病風(fēng)險(xiǎn)指標(biāo)）

Hemoglobin A1c參照標(biāo)準(zhǔn)（長期控糖指標(biāo)）

二、臨床研發(fā)類檢測試劑與試劑盒測定大量人類糖尿病及其并發(fā)癥的重要指標(biāo)，在該領(lǐng)域中Exocell公司提供的相關(guān)產(chǎn)品包括：

Apo B Test用于檢測人血漿中的apolipoprotein B

Collagen IV H用于檢測 樣本中的IV 型膠原

hFibronectin ELISA試劑盒用于檢測人血漿中的fibronectin

Nephrin ELISA試劑盒用于檢測尿液中的nephrin.

h-PODXL用于檢測人組織或尿液樣本中的podocalyxin

Beta-induced h3用于檢測人尿液中的BIG-H3，

Troponin – H用于檢測人血漿或血清中的 Troponin I，

TNF-sR2 用于檢測人尿/血漿/血清中的TNF-α可溶性受體2

三、Exocell公司提供的糖尿病及其并發(fā)癥的實(shí)驗(yàn)室研究相關(guān)產(chǎn)品，包括：

Albuwell M用于檢測小鼠樣本中的微白蛋白尿，

Nephrat II用于檢測大鼠樣本中的微白蛋白尿，

Albuwell C, O 及 P 用于檢測狗、綿羊及非人的靈長類動(dòng)物樣本中的微白蛋白尿，

Collagen IV M用于檢測小鼠和大鼠樣本中的IV型膠原，

Creatinine Companion用于檢測人和嚙齒類動(dòng)物的creatinine.

Glyco-Albumin R用于檢測大鼠血清中的糖化白蛋白，

Nephrin ELISA to measure rodent urinary nephrin.

CRP ELISA試劑盒用于檢測嚙齒類動(dòng)物血漿中的C-reactive蛋白.

Adiponectin ELISA試劑盒用于檢測人尿和血漿中的adiponectin，

Beta-induced h3用于檢測人尿中的BIG-H3，

Troponin M用于檢測小鼠血漿/血清中的Troponin I，

Troponin R用于檢測大鼠血漿/血清中的Troponin I，

PODXL–R用于檢測嚙齒類動(dòng)物尿液中的podpcalyxin ，

四、糖尿病及其并發(fā)癥研究相關(guān)的試劑及標(biāo)準(zhǔn)參照品，包括高特異性的單克隆抗體及高度純化的蛋白，，在該領(lǐng)域中Exocell公司提供的相關(guān)產(chǎn)品包括：

A717:抗糖化白蛋白單克隆抗體

E85: 抗糖化血紅素的單克隆抗體

ES12:抗糖化LDL的單克隆抗體

糖化血紅素片段(gly Hb, HbA1c, glyHbA0, HbA1a, b)

去糖的血紅素片段(degly Hb, degly HbA0)

糖化的白蛋白(NGA/SGA)

去糖化的白蛋白

部分使用Exocell公司產(chǎn)品的相關(guān)文獻(xiàn)：

  1、Albuwell M：

• American Journal Physiology Renal Physiology 293:F1657-1665, 2007
  Interference with TGF-B signalling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria
• American Journal Physiology Renal Physiology 292:F321-329, 2007
  Soluble betaglycan reduces renal damage progression in db/db mice
• Nephron Experimental Nephrology 105:e45-e52, 2007
  Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
• American Journal Physiology Renal Physiology 290:F214-F222, 2006
  Impact of genetic background on nephropathy in diabetic mice
• American Journal Physiology Heart Circ Physiology 290:H935-H940, 2006
  Angiotensin II hypertension is attenuated in interleukin-6 knockout mice
• American Journal Physiology Renal Physiology 291:F1315-F1322, 2006
  Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes
• American Journal Physiology Renal Physiology 290:F813-820, 2006
  SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
• American Journal Physiology Renal Physiology 290:F828-F837, 2006
  Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
• Nephron Experimental Nephrology 104:e23-e34, 2006
  Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice
• Journal American Society Nephrology 16:27-45, 2005
  Mouse models of diabetic nephropathy
• American Society Nephrology 16:1289-1299, 2005
  Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23
• Diabetes 54:2628-2637, 2005
  Characterization of susceptibility of inbred mouse strains to diabetic nephropathy
• American Journal Pathology 165:1243-1255, 2004
  Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules
• Hypertension 43:364-369, 2004
  Role for thromboxanes receptors in angiotensin-II-induced hypertension
• Journal Clinical Investigation 113:1390-1397, 2004
  Induction of B7-1 in podocytes is associated with nephritic syndrome
• Diabetes 53:2101-2109, 2004
  Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-?-deficient mice
• Journal American Society Nephrology 14:1200-1211, 2003
  Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant ?-actinin-4
• American Journal Pathology 162:1123-1137, 2003
  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
• Kidney International 64:1978-1985, 2003
  Gene expression profile in diabetic KK/Ta mice
• Journal of Immunology 170:5658-5666, 2003
  CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration

      2、Glycacor：

• Atherosclerosis 202:162-168, 2009
  Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro
• Immunopharmacology Immunotoxicology 15:1-12, 2008
  Evaluation of serum biomarkers in nutritional disorders: Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects
• Nutrition Metabolism & Cardiovascular Disease 17:6-12, 2007
  Glycated apolipoprotein B and myocardial infarction
• Circulation 109:1750-1755, 2004
  Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes
• Diabetes Technology & Therapeutics 6:348-356, 2004
  Increased plasma glycated low-density lipoprotein concentrations in diabetes: A marker of atherogenic risk
• Journal American Society Nephrology 10:332-341, 1999
  Non-insulin dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients
• Nephrology Dialysis Transplantation 12:1336-1343, 1997
  Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells

3、Nephrat：

• Cell Biochemistry Biophysics 48:147-157, 2007
  Novel inhibitors of glycation and AGE formation
• American Journal Physiology Regul Integr Comp Physiology 292:R769-R777, 2007
  17-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney
• Diabetes 56:1842-1849, 2007
  Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation
• American Journal Physiology Renal Physiology 290:F828-F837, 2006
  Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
• Laboratory Investigation 86:357-368, 2006
  Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy
• FASEB Journal 20:E150-E159, 2006
  Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers
• American Journal Physiology Regul Integr Comp Physiology 290:R435-R441, 2006
  Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes
• Laboratory Investigation 86:927-939, 2006
  Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy
• American Journal Physiology Renal Physiology 289:F442-450, 2005
  Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone
• Diabetologia 46:1140-1152, 2003
  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
• Journal American Society Nephrology 14:709-720, 2003
  Delayed treatment with lithospermate B attenuates experimental diabetic renal injury
• Journal American Society Nephrology 14:3178-3187, 2003
  Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen ?5(IV) in experimental diabetic nephropathy and ion glucose-stimulated podocytes
• American Journal Pathology 158:1733-1741, 2001
  A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis
• American Journal Society Nephrology 12:993-1000, 2001
  Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes

      4、Collagen Type IV

• Diabetologia 51:198-207, 2008
  Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells
• Nephron Experimental Nephrology 105:e45-e52, 2007
  Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
• American Journal Physiology Renal Physiol 292:F789-F795, 2007
  Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
• American Journal Physiology Renal Physiology 290:F813-820, 2006
  SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
• Kidney International 68:1554-1561, 2005
  Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy
• Kidney International 64:1632-1642, 2003
  Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells
• Metabolism 50:1435-1440, 2001
  Increased urinary type IV collagen marks the development of glomerular [athology in diabetic db/db mice
• Diabetes Care 24:914-918, 2001
  Increased collagen IV excretion in diabetes
• Diabetes Care 24:1324-1327, 2001
  Serum type IV collagen in diabetic patients at risk for nephropathy

5、Nephrin：

• PLoS One 7(5):e36041, 2012
  Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross sectional study
• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and ?ig-h3 in women with preeclampsia

6、Podocalyxin：

• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia

7、 βig-h3：

• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia

詳細(xì)公司及產(chǎn)品信息請(qǐng)?jiān)L問：http://www.exocell。。ｃｏｍ/

世界*實(shí)驗(yàn)材料供應(yīng)商Exocell正式授權(quán)上海起發(fā)為其中國代理，Exocell在一直是行業(yè)的*,一直為廣大科研客戶提供zui為的產(chǎn)品和服務(wù),上海起發(fā)一直秉承為中國科研客戶帶來的產(chǎn)品，的服務(wù)， 簽約Exocell就是為了給廣大科研客戶帶來更加完善的產(chǎn)品和服務(wù),您的滿意將是我們zui大的收獲

Exocell中國代理，Exocell上海代理，Exocell北京代理，Exocell廣東代理，Exocell江蘇代理 Exocell湖北代理, Exocell天津, Exocell黑龍江代理, Exocell內(nèi)蒙古代理, Exocell吉林代理, Exocell福建代理, Exocell江蘇代理, Exocell浙江代理, Exocell四川代理,

我們公司zui大優(yōu)勢(shì)是強(qiáng)大的采購，

1：基本什么都能進(jìn)口，血清，抗體，耗材，還有部分限制進(jìn)口的，

2： 貨品全，現(xiàn)經(jīng)營過700多個(gè)品牌，基本所有生物試劑耗材都可以進(jìn)口，特別是冷偏的產(chǎn)品那就更有優(yōu)勢(shì)，

3：提供加急服務(wù)，一般1-2周到貨，超過時(shí)限加急費(fèi)全免

4：價(jià)格公道，絕大部分價(jià)格有優(yōu)勢(shì)，當(dāng)然不能保證100%產(chǎn)品都是,因?yàn)橐馕吨鴽]有服務(wù).

5：良好的信譽(yù)，大部分客戶我們提供貨到付款服務(wù)，客戶包括清華，北大 交大 復(fù)旦，中山等100多所大學(xué)，ROCHE，阿斯利康，國藥 ，fisher等500多家公司

6：我們還是santa,Advanced Biotechnologies Inc;Athens Research & Technology, bangs, BBInternational, crystalchem, dianova, FD Neurotechnologies, Inc. FormuMax Scientific, Inc; Genebridege; Glycotope Biotechnology GmbH; iduron; Innovative Research of America； Ludger ； neuroprobe; omicronbio; Polysciences; prospecbi; QA-BIO；quickzyme；RESEARCH DIETS, INC；sterlitech；sysy；TriLink BioTechnologies, Inc；worthington-biochem;zyagen;......幾十家國外公司授權(quán)代理

7：我們還從事invitrogen，qiagen; abcam ;sigma;neb; roche;merck; rnd; BD; GE; pierce; BioLegend....等*批發(fā)